Literature DB >> 21120793

Insulin resistance in the control of body fat distribution: a new hypothesis.

A T Ali1, W F Ferris, N H Naran, N J Crowther.   

Abstract

Obesity causes insulin resistance, which is a prime etiological factor for type 2 diabetes, dyslipidemia, and cardiovascular disease. However, insulin resistance may be a normal physiological response to obesity that limits further fat deposition and which only has pathological effects at high levels. The current hypothesis suggests that in obesity the initial deposition of triglycerides occurs in subcutaneous adipose tissue and as this increases in size insulin resistance will rise and limit further subcutaneous lipid accumulation. Triglycerides will then be diverted to the visceral fat depot as well as to ectopic sites. This leads to a substantial rise in insulin resistance and the prevalence of its associated disorders. Evidence supporting this hypothesis includes studies showing that in lean subjects the prime determinant of insulin resistance is BMI, that is, subcutaneous fat whilst in overweight and obese subjects it is waist circumference and visceral adiposity. It has also been shown that the metabolic syndrome suddenly increases in prevalence at high levels of insulin resistance and we suggest that this is due to the diversion of lipids from the subcutaneous to the visceral depot. This system may have functioned in our evolutionary past to limit excessive adiposity by causing lipid deposition to occur at a site that has maximal effects on insulin resistance but involves minimal weight gain. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120793     DOI: 10.1055/s-0030-1269851

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Serum Caveolin-1 Level is Inversely Associated with Serum Vaspin, Visfatin, and HbA1c in Newly Diagnosed Men with Type-2 Diabetes.

Authors:  Hameed Hussein Ali; Khalid Al-Rawi; Yousif Khalaf; Shakir Alaaraji; Bilal Aldahham; Muthanna Awad; Osamah Al-Ani; Faisal Al-Ani; Aus Tariq Ali
Journal:  Rep Biochem Mol Biol       Date:  2022-07

2.  Gestational Diabetes and the Offspring: Implications in the Development of the Cardiorenal Metabolic Syndrome in Offspring.

Authors:  Liliana Garcia-Vargas; Sonya S Addison; Ravi Nistala; Damascene Kurukulasuriya; James R Sowers
Journal:  Cardiorenal Med       Date:  2012-04-12       Impact factor: 2.041

3.  The current waist circumference cut point used for the diagnosis of metabolic syndrome in sub-Saharan African women is not appropriate.

Authors:  Nigel J Crowther; Shane A Norris
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

4.  Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age.

Authors:  Janet A Rowan; Elaine C Rush; Victor Obolonkin; Malcolm Battin; Trecia Wouldes; William M Hague
Journal:  Diabetes Care       Date:  2011-10       Impact factor: 19.112

5.  Metformin therapy during pregnancy: good for the goose and good for the gosling too?

Authors:  Denice S Feig; Robert G Moses
Journal:  Diabetes Care       Date:  2011-10       Impact factor: 19.112

6.  Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus.

Authors:  Zhaoyi Huang; Xiaohu Xu; Fuer Lu; Nan Wang; Guang Chen; Yan Zhao; Xin Zou; Kaifu Wang; Hui Dong; Lijun Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-10       Impact factor: 2.629

7.  Analysis of Factors Influencing Mayo Adhesive Probability Score in Partial Nephrectomy.

Authors:  Chaoyue Ji; Shiying Tang; Kunlin Yang; Gengyan Xiong; Dong Fang; Cuijian Zhang; Xuesong Li; Liqun Zhou
Journal:  Med Sci Monit       Date:  2017-12-20

8.  Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity.

Authors:  Stefania Carobbio; Rachel M Hagen; Christopher J Lelliott; Marc Slawik; Gema Medina-Gomez; Chong-Yew Tan; Audrey Sicard; Helen J Atherton; Nuria Barbarroja; Mikael Bjursell; Mohammad Bohlooly-Y; Sam Virtue; Antoinette Tuthill; Etienne Lefai; Martine Laville; Tingting Wu; Robert V Considine; Hubert Vidal; Dominique Langin; Matej Oresic; Francisco J Tinahones; Jose Manuel Fernandez-Real; Julian L Griffin; Jaswinder K Sethi; Miguel López; Antonio Vidal-Puig
Journal:  Diabetes       Date:  2013-08-06       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.